Latest On DiaMedica Therapeutics Inc (DMAC):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-16 12:52 EST | News | DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-03-29 11:42 EST | News | DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-28 21:07 EST | News | DiaMedica Therapeutics GAAP EPS of -$0.52 in-line | N/A | |
| 2022-11-30 16:32 EST | News | DiaMedica: What's Happened And What's The Value Here | N/A | |
| 2022-11-09 23:13 EST | News | DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03 | N/A | |
| 2022-10-27 07:45 EST | News | DiaMedica stock slides 17% after hours as FDA maintains clinical hold on DM199 trial | N/A | |
| 2022-08-12 01:34 EST | News | DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-11 08:38 EST | News | DiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.05 | N/A | |
| 2022-07-06 21:27 EST | News | FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold | N/A | |
| 2022-05-16 11:12 EST | News | DiaMedica Therapeutics Inc. 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-05-07 00:58 EST | News | DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-05 02:30 EST | News | DiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.07 | N/A | |
| 2022-03-15 22:19 EST | News | DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-15 02:31 EST | News | DiaMedica Therapeutics GAAP EPS of -$0.65 beats by $0.08 | N/A | |
| 2022-01-05 20:09 EST | News | DiaMedica Therapeutics appoints chief medical officer | N/A | |
| 2021-11-12 00:43 EST | News | DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-06 00:33 EST | News | DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S. | N/A | |
| 2021-09-30 13:30 EST | News | DiaMedica gets FDA Fast Track status for acute ischemic stroke treatment DM199 | N/A | |
| 2021-09-27 16:22 EST | News | DiaMedica Therapeutics to undertake $30M private equity offering | N/A | |
| 2021-09-21 16:39 EST | News | DiaMedica Therapeutics (DMAC) Investor Presentation - Slideshow | N/A | |
| 2021-08-12 15:59 EST | News | DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-11 19:36 EST | News | DiaMedica Therapeutics EPS beats by $0.05 | N/A | |
| 2021-07-21 05:39 EST | News | DiaMedica: Undercovered Stroke Drug Company With Decent Data | N/A | |
| 2021-07-21 05:17 EST | News | Diamedica shows mixed results for kidney disease therapy in mid-stage study | N/A | |
| 2021-07-21 04:53 EST | News | DiaMedica Therapeutics adds two industry veterans to its board of directors | N/A | |
| 2021-05-06 10:44 EST | News | DiaMedica Therapeutics reports Q1 results | N/A | |
| 2021-03-18 12:32 EST | Analyst Rating | The Analyst Target Price has increased from $20.67 to $22.17. | Buy | |
| 2021-03-12 11:29 EST | Analyst Rating | The Analyst Target Price has increased from $19.83 to $20.67. | Buy | |
| 2021-03-12 02:43 EST | News | DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-11 15:30 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-11 11:29 EST | Earnings Estimate | An EPS average of -$1.19 is estimated for the 2022 year. | Sell | |
| 2021-03-11 11:29 EST | Earnings Estimate | An EPS average of -$0.76 is estimated for the 2021 year. | Sell | |
| 2021-03-11 11:29 EST | Earnings Estimate | An EPS average of -$0.19 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-11 06:01 EST | News | DiaMedica Therapeutics EPS misses by $0.06 | N/A | |
| 2021-02-18 11:27 EST | Analyst Rating | The Analyst Target Price has increased from $16.2 to $19.83. | Buy | |
| 2021-01-05 11:39 EST | Analyst Rating | The Analyst Target Price has increased from $13.4 to $16.2. | Buy | |
| 2020-12-17 11:47 EST | Earnings Estimate | An EPS average of -$0.13 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-12-17 11:47 EST | Earnings Estimate | An EPS average of -$0.16 is estimated for the quarter ending on December 31, 2020. | Buy | |
| 2020-12-17 11:47 EST | Analyst Rating | The Analyst Target Price has increased from $0 to $13.4. | Buy | |
| 2020-12-10 10:57 EST | News | DiaMedica rises 6% on successful Type B meeting with FDA for DM199 study in acute ischemic stroke | N/A | |
| 2020-11-26 19:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-10 19:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 07:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 05:35 EST | News | DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-07 15:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 11:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 07:04 EST | News | DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation | N/A | |
| 2020-11-05 03:04 EST | News | DiaMedica Therapeutics EPS misses by $0.04 | N/A | |
| 2020-09-26 12:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:42 EST | Financials | Company financials have been released. | Neutral | |
About DiaMedica Therapeutics Inc (DMAC):
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
General
- Name DiaMedica Therapeutics Inc
- Symbol DMAC
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 10
- Last Split Factor1:20
- Last Split Date2018-11-15
- Fiscal Year EndDecember
- IPO Date2008-01-04
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.diamedica.com
View More
Valuation
- Price/Book (Most Recent Quarter) 7.28
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.79
- Next Year EPS Estimate -$1.30
- Next Quarter EPS Estimate -$0.19
- Return on Assets -43%
- Return on Equity -73%
- Earnings Per Share -$0.90
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 180.81 million
- EBITDA -9387000
- Analyst Target Price $22.17
- Book Value Per Share $1.39
View More
Share Statistics
- Shares Outstanding 18.78 million
- Shares Float 16.41 million
- % Held by Insiders 672%
- % Held by Institutions 39.31%
- Shares Short 116640
- Shares Short Prior Month 82969
- Short Ratio 0.7
- Short % of Float 1%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 2.43
- 52 Week High $10.88
- 52 Week Low $1.87
- 50 Day Moving Average 9.19
- 200 Day Moving Average 6.69
View More
Dividends
- Dividend Date 2018-11-15
- ExDividend Date N/A
- Dividend Yield 0%
View More
DiaMedica Therapeutics Inc (DMAC) Dividend Calendar:
DMAC's last dividend payment was made to shareholders on November 15, 2018.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
DiaMedica Therapeutics Inc (DMAC) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-10 | $N/A | -$0.23 | -$0.16 | -41.54% |
| 2020-09-30 | 2020-11-04 | $N/A | -$0.19 | -$0.15 | -29.52% |
| 2020-06-30 | 2020-08-11 | $N/A | -$0.17 | -$0.14 | -25.93% |
| 2020-03-31 | 2020-05-13 | $N/A | -$0.19 | -$0.29 | 33.33% |
| 2019-12-31 | 2020-03-23 | $N/A | -$0.21 | -$0.25 | 16% |
| 2019-09-30 | 2019-11-13 | $N/A | -$0.20 | -$0.21 | 4.76% |
| 2019-06-30 | 2019-08-13 | $N/A | -$0.21 | -$0.26 | 18.19% |
| 2019-03-31 | 2019-05-13 | $N/A | -$0.27 | -$0.20 | -35% |
| 2018-12-31 | 2019-03-19 | $-3657 | -$0.11 | -$0.26 | 57.69% |
| 2018-09-30 | 2018-12-10 | $503657 | -$0.07 | ||
| 2018-06-30 | 2018-08-30 | $N/A | -$0.46 | ||
| 2018-03-31 | 2018-04-30 | $N/A | -$0.09 | ||
| 2017-09-30 | 2017-11-27 | $N/A | -$0.15 | ||
| 2017-06-30 | 2017-08-29 | $N/A | -$0.18 | ||
| 2017-03-31 | 2017-04-27 | $N/A | -$0.24 | ||
| 2016-09-30 | 2016-11-29 | $N/A | -$0.20 | ||
| 2016-06-30 | 2016-08-29 | $N/A | -$0.12 | ||
| 2016-03-31 | 2016-04-29 | $N/A | -$0.08 | ||
| 2015-09-30 | 2015-11-30 | $N/A | -$0.07 | ||
| 2015-06-30 | 2015-08-31 | $N/A | -$0.10 | ||
| 2015-03-31 | 2015-04-30 | $N/A | -$0.14 | ||
| 2014-09-30 | 2014-11-28 | $N/A | -$0.40 | -$0.20 | -100% |
| 2014-06-30 | 2014-08-28 | $N/A | -$0.40 | -$0.60 | 33.33% |
| 2014-03-31 | 2014-04-30 | $N/A | -$0.40 | -$0.40 | 0% |
| 2013-09-30 | 2013-11-28 | $N/A | -$0.47 | ||
| 2013-06-30 | 2013-08-28 | $N/A | -$0.80 | ||
| 2013-03-31 | 2013-03-31 | $N/A | -$1.08 | ||
| 2012-12-31 | 2012-12-31 | $N/A | -$1.25 | ||
| 2012-09-30 | 2012-09-30 | $N/A | -$1.02 |
DiaMedica Therapeutics Inc (DMAC) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
DiaMedica Therapeutics Inc (DMAC) Chart:
DiaMedica Therapeutics Inc (DMAC) News:
Below you will find a list of latest news for DiaMedica Therapeutics Inc (DMAC) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
DiaMedica Therapeutics Inc (DMAC) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0.04 | CALL | 0 | 40 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0.1 | PUT | 0 | 10 | 87.93 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 335.69 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 362.23 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 0.72 | CALL | 0 | 23 | 0 | TRUE | 0 | 0 |
| 2024-07-19 | 5 | 0.05 | CALL | 0 | 88 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 7.5 | 0.1 | CALL | 0 | 35 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 2.5 | 0.35 | PUT | 1 | 92 | 81.6 | FALSE | 0.35 | 0 |
| 2024-07-19 | 5 | 1.85 | PUT | 0 | 2 | 184.31 | TRUE | 0 | 0 |
| 2024-07-19 | 7.5 | 0 | PUT | 0 | 0 | 176.69 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 0.6 | CALL | 0 | 14 | 69.25 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 0.2 | CALL | 0 | 1 | 554.4 | FALSE | 0 | 0 |
| 2024-10-18 | 7.5 | 0.1 | CALL | 0 | 379 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 2.5 | 0.45 | PUT | 0 | 3 | 78.13 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 0 | PUT | 0 | 0 | 117.9 | TRUE | 0 | 0 |
| 2024-10-18 | 7.5 | 0 | PUT | 0 | 0 | 150.31 | TRUE | 0 | 0 |
Latest DMAC Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 3:48 PM EST | 100 | $2.29 |
DiaMedica Therapeutics Inc (DMAC) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920012348/0001437749-20-012348-index.htm |
| 2020-01-06 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1401040/000000000020000113/0000000000-20-000113-index.htm |
| 2020-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1401040/000093583620000089/0000935836-20-000089-index.htm |
| 2019-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000064/0001235802-19-000064-index.htm |
| 2019-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000065/0001235802-19-000065-index.htm |
| 2019-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000066/0001235802-19-000066-index.htm |
| 2019-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000067/0001235802-19-000067-index.htm |
| 2019-08-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000105/0001235802-19-000105-index.htm |
| 2019-08-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000106/0001235802-19-000106-index.htm |
| 2019-08-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000107/0001235802-19-000107-index.htm |
| 2019-08-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000108/0001235802-19-000108-index.htm |
| 2019-11-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000130/0001235802-19-000130-index.htm |
| 2019-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000131/0001235802-19-000131-index.htm |
| 2020-06-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580220000049/0001235802-20-000049-index.htm |
| 2020-06-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580220000050/0001235802-20-000050-index.htm |
| 2020-06-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580220000051/0001235802-20-000051-index.htm |
| 2020-06-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580220000052/0001235802-20-000052-index.htm |
| 2020-06-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580220000053/0001235802-20-000053-index.htm |
| 2020-06-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580220000054/0001235802-20-000054-index.htm |
| 2020-06-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1401040/000123580220000055/0001235802-20-000055-index.htm |
| 2020-01-31 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1401040/000138713120000815/0001387131-20-000815-index.htm |
| 2019-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774919016566/0001437749-19-016566-index.htm |
| 2019-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1401040/000143774919016595/0001437749-19-016595-index.htm |
| 2019-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774919020938/0001437749-19-020938-index.htm |
| 2019-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774919022681/0001437749-19-022681-index.htm |
| 2019-11-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1401040/000143774919022682/0001437749-19-022682-index.htm |
| 2020-01-02 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1401040/000143774920000070/0001437749-20-000070-index.htm |
| 2020-01-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920000102/0001437749-20-000102-index.htm |
| 2020-01-07 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1401040/000143774920000296/0001437749-20-000296-index.htm |
| 2020-02-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1401040/000143774920002238/0001437749-20-002238-index.htm |
| 2020-02-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920002240/0001437749-20-002240-index.htm |
| 2020-02-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1401040/000143774920002327/0001437749-20-002327-index.htm |
| 2020-02-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920002598/0001437749-20-002598-index.htm |
| 2020-03-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920005905/0001437749-20-005905-index.htm |
| 2020-03-23 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1401040/000143774920005906/0001437749-20-005906-index.htm |
| 2020-04-20 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1401040/000143774920007997/0001437749-20-007997-index.htm |
| 2020-04-20 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1401040/000143774920007998/0001437749-20-007998-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920010597/0001437749-20-010597-index.htm |
| 2020-05-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1401040/000143774920010599/0001437749-20-010599-index.htm |
| 2020-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920012348/0001437749-20-012348-index.htm |
| 2020-08-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1401040/000143774920016682/0001437749-20-016682-index.htm |
| 2020-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920016685/0001437749-20-016685-index.htm |
| 2020-08-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1401040/000143774920017103/0001437749-20-017103-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920017105/0001437749-20-017105-index.htm |
| 2020-08-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920017512/0001437749-20-017512-index.htm |
| 2020-08-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1401040/000143774920017514/0001437749-20-017514-index.htm |
| 2020-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1401040/000143774920022536/0001437749-20-022536-index.htm |
| 2020-11-04 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1401040/000143774920022537/0001437749-20-022537-index.htm |
| 2020-01-09 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1401040/999999999520000060/9999999995-20-000060-index.htm |
DiaMedica Therapeutics Inc (DMAC) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of DiaMedica Therapeutics Inc (DMAC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 672%Institutional Ownership: 3931%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-08-19 | Scott Kellen | CFO and Secretary | Buy | 3,000.00 | 2.43 | 7,290.00 | 10,290.00 | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000108/0001235802-19-000108-index.htm |
| 2020-06-01 | James T. Parsons | Director | Buy | 8,102.00 | 4.59 | 37,188.18 | 14,202.00 | https://www.sec.gov/Archives/edgar/data/1401040/000123580220000050/0001235802-20-000050-index.htm |
| 2019-08-16 | Dietrich John Pauls | President and CEO | Buy | 1,000.00 | 2.68 | 2,676.90 | 30,804.00 | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000105/0001235802-19-000105-index.htm |
| 2019-08-16 | Richard D. Pilnik | Director | Buy | 7,840.00 | 2.56 | 20,039.04 | 50,678.00 | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000107/0001235802-19-000107-index.htm |
| 2020-06-01 | Richard D. Pilnik | Director | Buy | 10,168.00 | 4.59 | 46,671.12 | 60,846.00 | https://www.sec.gov/Archives/edgar/data/1401040/000123580220000049/0001235802-20-000049-index.htm |
| 2019-08-16 | HARRY W JR ALCORN | Chief Medical Officer | Buy | 7,260.00 | 2.67 | 19,365.32 | 8,260.00 | https://www.sec.gov/Archives/edgar/data/1401040/000123580219000106/0001235802-19-000106-index.htm |
| 2020-06-01 | Randall Michael Giuffre | Director | Buy | 7,784.00 | 4.59 | 35,728.56 | 93,588.00 | https://www.sec.gov/Archives/edgar/data/1401040/000123580220000051/0001235802-20-000051-index.htm |